Medical News

RSS

A new practice: The doctor will see you

Catherine Arnst, writing for Kaiser Health News in collaboration with The Boston Globe, reports: "Dr. Dennis M. Dimitri, a family physician, runs a pretty unusual office. Few appointments are accepted in advance. Instead, patients call in the morning and are assigned a time slot later that day.

15 Jul 2010

Aeterna Zentaris' partner Keryx receives FDA orphan-drug designation for perifosine in neuroblastoma

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc., has been granted orphan-drug designation by the U.S. Food and Drug Administration for perifosine, Aeterna Zentaris' novel, potentially first-in-class, oral Akt inhibitor, for the treatment of neuroblastoma.

15 Jul 2010

Final rules for e-health rewards unveiled

The federal government has issued new regulations defining the "meaningful use" of electronic medical records, a requirement doctors must fulfill in order to gain funds from a $27-billion pot set aside in the 2009 stimulus law, The New York Times reports. "A doctor can receive up to $44,000 under Medicare and $63,750 under Medicaid, while a hospital can receive millions of dollars, depending on its size."

15 Jul 2010

Tepha receives $3.2 million credit facility from GE Capital

GE Capital, Healthcare Financial Services today announced it has provided a $3.2 million credit facility to Tepha, Inc. The financing provides Tepha with working capital as it expands global commercialization efforts.

15 Jul 2010

Aestus, Eisai collaborate to research and develop novel therapeutics for psychiatric disorders

Aestus Therapeutics, Inc. announced today a collaboration agreement with Eisai Inc. on research and development of novel therapeutics for the treatment of psychiatric disorders. The multi-year collaboration will entail pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.

15 Jul 2010

Health insurers confront dual uncertainties of recession, overhaul

Health insurers' Wall Street prospects remain uncertain as details of the health overhaul have yet to be mapped out, according to a Dow Jones Newswires/The Wall Street Journal brief. "While the federal overhaul of the health-care system could add millions of new members to companies' rolls, it also places new taxes and restrictions on the industry.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Starpharma gets FDA nod to start phase 2 bacterial vaginosis study for VivaGel

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced it had received clearance from the US Food and Drug Administration (FDA) to commence a phase 2 study to investigate VivaGel® for the treatment of bacterial vaginosis (BV).

15 Jul 2010

Aboriginals smoke less cigarettes per day than others: Study

A new study showed that Aboriginal smokers residing in remote communities have a significantly lower consumption of cigarettes than the rest of the population. The study was published in the Australian and New Zealand Journal of Public Health on Wednesday.

14 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

OSI Electronics receives $4 million order from innovative medical device manufacturer

OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that OSI Electronics, a business within its Optoelectronic and Manufacturing division, has received an order of approximately $4 million for electronic sub-assemblies from an innovative medical device manufacturer.

14 Jul 2010

Aastrom commences extension study for control patients from Phase 2 IMPACT-DCM clinical trial

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced the initiation of an extension study for control patients from the company's ongoing open-label Phase 2 IMPACT-DCM clinical trial in patients with dilated cardiomyopathy (DCM).

14 Jul 2010

NIAID awards ATCC multimillion dollar MID-BRR contract

ATCC, the premier biological materials resource, services, and standards organization, has been awarded the National Institute of Allergy and Infectious Diseases, Microbiology and Infectious Diseases Biological Resource Repository ("MID-BRR") contract, ATCC announced today. The current value of the contract is $14,615,598 with the ultimate value of $115,733,409 over 7 years with an annual renewal.

14 Jul 2010

OraVerse MAA accepted for review in five key European countries

Sanofi-Aventis Deutschland GmbH and Novalar Pharmaceuticals, Inc. today announced that the Marketing Authorization Application (MAA) for OraVerse has been accepted for review by the regulatory agencies of the United Kingdom (UK), Germany, Italy, France and Spain. OraVerse is the first and only local anesthesia reversal agent that accelerates the return of normal sensation and function following routine dental procedures. OraVerse is approved for use in the U.S. by the Food and Drug Administration and sold by Novalar direct to U.S. dentists.

14 Jul 2010

BARRX Medical closes $15 million Series D financing

BARRX Medical, Inc. today announced the closing of a $15 million Series D financing, which was led by new investor Highland Capital Partners and joined by existing investors Delphi Ventures, Alloy Ventures, Frazier Healthcare Ventures, Sutter Hill Ventures, Greenspring Associates and others. BARRX Medical, Inc. develops endoscopic treatment solutions for treating precancerous lesions of the esophagus as well as other chronic gastrointestinal diseases.

14 Jul 2010

Samsung Medical Center, Pfizer form research partnership

Samsung Medical Center and the world's leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer.

14 Jul 2010

Trevena completes $35M Series B financing

Trevena, Inc., the leader in discovery and development of G-protein coupled receptor biased ligands, announced today that it has completed a $35 million Series B financing. Existing investors Polaris Venture Partners and New Enterprise Associates led the round, with all other existing Trevena investors - Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company - also participating in the financing.

14 Jul 2010

SANUWAVE Health introduces orthoPACE device in Europe

SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports the European launch of the orthoPACE device intended for use in orthopedic, trauma and sports medicine indications following CE mark approval last month.

14 Jul 2010

Pall enters new $500 million 5-year revolving credit facility

Pall Corporation today announced that it has entered into a new $500 million five-year revolving credit facility. The new facility replaces the Company's $500 million revolver that was due to expire in June 2011. This transaction follows on the recent refinancing of the Company's $280 million senior notes due in 2012 with proceeds of senior notes now due in 2020.

From Pall Corporation 14 Jul 2010

ZYTO announces launch of redesigned corporate website

ZYTO Corp, www.ZYTO.com, is pleased to announce the launch of its completely redesigned corporate website. The updated site is the result of extensive analysis, design, and programming.

14 Jul 2010